Detail akcie PTC Therapeutics online

Business Summary: PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, PTC Therapeutics, Inc. revenues increased from $593.6M to $1.57B. Net income totaled $817.6M vs. loss of $297.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 77% to $31.9M.